PDCD1 and neoplasm: In simulations, the responder shows complete tumor regression in response to both 10 mg/kg Q3Dx3 anti-PD-1 and 10 mg/kg Q3Dx3 anti-PD-L1, while the non-responder shows continued tumor growth when treated with either anti-PD-1 or anti-PD-L1 (data not shown).